ReviewCurrent sleep medicine reports2025
Integrating Assessment of Circadian Rhythmicity to Improve Treatment Outcomes for Circadian Rhythm Sleep-Wake Disorders: Updates on New Treatments.
Review in Current sleep medicine reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Purpose of Review: Despite advancements in basic circadian research, development of new diagnostic and treatment strategies for circadian rhythm sleep-wake disorders (CRSWDs) has been slow. Here, we review the most recent innovations in human circadian assessment and emerging new therapies for CRSWDs. Recent Findings: Researchers have improved existing circadian assessment methods to overcome logistical barriers and developed novel circadian assessment methods. New treatments for CRSWDs involve pharmacological and behavioral treatments that modulate circadian phase, amplitude, and/or robustness of the central circadian clock. Summary: Commercialization of these emerging tools will require overcoming barriers, such as additional testing to confirm the underlying pathology and mechanism of action of potential treatments. Clinicians and scientists are also called to survey adjacent fields and adopt existing diagnostic tools that may offer diagnostic clarity in CRSWDs. Lastly, we must continue to advocate for medical insurance coverage of current and future tools and technologies to improve patient care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.